| Document And Entity Information - USD ($) | Dec. 31, 2022 | Apr. 21, 2023 | Jun. 30, 2022 |
| Document Information [Line Items] | |||
| Entity, Registrant Name | NOVABAY PHARMACEUTICALS, INC. | ||
| Document, Type | 10-K/A | ||
| Document, Annual Report | true | ||
| Document, Period End Date | Dec. 31, 2022 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document, Fiscal Period Focus | FY | ||
| Document, Fiscal Year Focus | 2022 | ||
| Document, Transition Report | false | ||
| Entity, File Number | 001-33678 | ||
| Entity, Incorporation, State or Country Code | DE | ||
| Entity, Tax Identification Number | 68-0454536 | ||
| Entity, Address, Address Line One | 2000 Powell Street, Suite 1150 | ||
| Entity, Address, City or Town | Emeryville | ||
| Entity, Address, State or Province | CA | ||
| Entity, Address, Postal Zip Code | 94608 | ||
| City Area Code | 510 | ||
| Local Phone Number | 899-8800 | ||
| Title of 12(b) Security | Common Stock | ||
| Trading Symbol | NBY | ||
| Security Exchange Name | NYSE | ||
| Entity, Well-known Seasoned Issuer | No | ||
| Entity, Voluntary Filers | No | ||
| Entity, Current Reporting Status | Yes | ||
| Entity, Interactive Data, Current | Yes | ||
| Entity, Emerging Growth Company | false | ||
| Entity, Filer Category | Non-accelerated Filer | ||
| Entity, Small Business | true | ||
| ICFR Auditor Attestation Flag | false | ||
| Entity, Shell Company | false | ||
| Entity, Public Float | $ 10,875,498 | ||
| Entity, Common Stock Shares, Outstanding | 2,194,444 | ||
| Auditor Name | WithumSmith+Brown, PC | ||
| Auditor Firm ID | 100 | ||
| Auditor Location | San Francisco, CA | ||
| Amendment Description | NovaBay Pharmaceuticals, Inc. is filing this Amendment No. 1 on Form 10-K/A (this “Form 10-K/A”) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Original Form 10-K”) that was filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023 for the sole purpose of including the information required by Part III of Form 10-K. This Part III information was previously omitted from the Original Form 10-K in reliance on General Instruction G(3) to Form 10-K, which permits the information in Part III to be incorporated in Form 10-K by reference to the Company’s definitive proxy statement if such statement is filed no later than 120 days after the end of our fiscal year. As required by Rule 12b-15, in connection with this Form 10-K/A, the Company’s Principal Executive Officer and Principal Financial Officer are providing Rule 13a-14(a) certifications included herein. Except as explicitly set forth herein, this Form 10-K/A does not purport to modify or update the disclosures in, or exhibits to, the Original Form 10-K or to update the Original Form 10-K to reflect events occurring after the date of such filing. | ||
| Amendment Flag | true | ||
| Entity, Central Index Key | 0001389545 |
